- Home
- BCDA vs FOXO Comparison
BCDA vs FOXO Comparison
Compare BCDA & FOXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- FOXO
- Stock Information
- Founded
- BCDA N/A
- FOXO 2019
- Country
- BCDA United States
- FOXO United States
- Employees
- BCDA N/A
- FOXO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- FOXO Retail: Computer Software & Peripheral Equipment
- Sector
- BCDA Health Care
- FOXO Technology
- Exchange
- BCDA Nasdaq
- FOXO Nasdaq
- Market Cap
- BCDA 7.9M
- FOXO 8.0M
- IPO Year
- BCDA N/A
- FOXO N/A
- Fundamental
- Price
- BCDA $2.18
- FOXO $0.23
- Analyst Decision
- BCDA Strong Buy
- FOXO
- Analyst Count
- BCDA 1
- FOXO 0
- Target Price
- BCDA $25.00
- FOXO N/A
- AVG Volume (30 Days)
- BCDA 52.4K
- FOXO 7.6M
- Earning Date
- BCDA 11-13-2024
- FOXO 11-19-2024
- Dividend Yield
- BCDA N/A
- FOXO N/A
- EPS Growth
- BCDA N/A
- FOXO N/A
- EPS
- BCDA N/A
- FOXO N/A
- Revenue
- BCDA $71,000.00
- FOXO $1,341,000.00
- Revenue This Year
- BCDA N/A
- FOXO N/A
- Revenue Next Year
- BCDA N/A
- FOXO N/A
- P/E Ratio
- BCDA N/A
- FOXO N/A
- Revenue Growth
- BCDA N/A
- FOXO 196.03
- 52 Week Low
- BCDA $1.63
- FOXO $0.13
- 52 Week High
- BCDA $8.85
- FOXO $1.30
- Technical
- Relative Strength Index (RSI)
- BCDA 49.10
- FOXO 41.10
- Support Level
- BCDA $2.05
- FOXO $0.19
- Resistance Level
- BCDA $2.36
- FOXO $0.38
- Average True Range (ATR)
- BCDA 0.21
- FOXO 0.05
- MACD
- BCDA -0.00
- FOXO 0.00
- Stochastic Oscillator
- BCDA 46.43
- FOXO 22.84
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.